Viatris Acquires Aculys Pharma to Secure CNS Assets and Japan/APAC Rights
October 15, 2025
Viatris Inc. has acquired clinical-stage Aculys Pharma, Inc., obtaining exclusive development and commercialization rights in Japan for pitolisant and rights in Japan and select Asia‑Pacific markets for Spydia (diazepam) nasal spray. The deal includes an upfront payment to Aculys shareholders with additional milestone and royalty payments, and is intended to strengthen Viatris' presence and CNS capabilities in Japan.
- Buyers
- Viatris Inc.
- Targets
- Aculys Pharma, Inc.
- Sellers
- Aculys Pharma shareholders
- Industry
- Pharmaceuticals
- Location
- Japan
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.